首页> 外文OA文献 >Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study

【2h】

Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study

机译：利妥昔单抗联合化学疗法作为中国弥漫性大B细胞淋巴瘤患者常规治疗的一线治疗：一项前瞻性，多中心，非干预性研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者

展开▼
作者单位

展开▼
年度 2016
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study [J] . Jianqiu Wu, Yongping Song, Liping Su, BMC Cancer . 2016,第1期

机译：利妥昔单抗联合化学疗法作为中国弥漫性大B细胞淋巴瘤患者常规治疗的一线治疗：一项前瞻性，多中心，非干预性研究
2. Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): Six-year results from a prospective, multicentre, non-interventional study in 2,484 patients [J] . WendlerJ., BurmesterG.R., S?rensenH., Arthritis research & therapy. . 2014,第2期

机译：常规治疗类风湿关节炎患者使用利妥昔单抗（GERINIS）：一项对2,484位患者的前瞻性，多中心，非干预性研究的六年结果
3. Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients [J] . Joerg Wendler, Gerd R Burmester, Helmut S?rensen, Arthritis Research . 2014,第2期

机译：常规治疗类风湿关节炎患者使用利妥昔单抗（GERINIS）：一项对2,484位患者进行的前瞻性，多中心，非干预性研究的六年结果
4. Pathological Analysis of Diffuse Large B-Cell Lymphoma and Clinical Treatment with Chinese and Western Medicine [C] . Xianhui Liu, Xiaona Guo, Chunsheng Yan International Conference on Management, Education, Information and Control . 2016

机译：弥漫性大B细胞淋巴瘤的病理分析及中西医临床治疗
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective multicentre non-interventional study [O] . Jianqiu Wu, Yongping Song, Liping Su, 2016

机译：利妥昔单抗联合化学疗法作为中国弥漫性大B细胞淋巴瘤患者常规治疗的一线治疗：一项前瞻性多中心非干预性研究
7. Three-year Follow-up on the Safety and Effectiveness of Rituximab Plus Chemotherapy as First-Line Treatment of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Real-World Clinical Settings in China [O] . Jian-Qiu Wu, Yong-Ping Song, Li-Ping Su, 2018

机译：促进利妥昔单抗加上化疗的三年随访，作为弥漫性大型B细胞淋巴瘤和滤泡淋巴瘤在中国的综合性临床环境中

Rituximab plus chemotherapy as first-line treatment in Chinese patients with diffuse large B-cell lymphoma in routine practice: a prospective, multicentre, non-interventional study

著录项

引文网络

相似文献

相关主题

期刊订阅